OncoVista Innovative Financials
| OVIT Stock | USD 0.0001 0.00 0.00% |
OncoVista |
Please note, the imprecision that can be found in OncoVista Innovative's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of OncoVista Innovative Therapies. Check OncoVista Innovative's Beneish M Score to see the likelihood of OncoVista Innovative's management manipulating its earnings.
OncoVista Innovative Stock Summary
OncoVista Innovative competes with Pmv Pharmaceuticals, MediciNova, Pharvaris, PepGen, and Anebulo Pharmaceuticals. OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company was founded in 2004 and is based in San Antonio, Texas. ONCOVISTA INNOVATIVE operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 14785 Omicron Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.oncovista.com |
| Phone | 210 677 6000 |
| Currency | USD - US Dollar |
OncoVista Innovative Key Financial Ratios
OncoVista Innovative's financial ratios allow both analysts and investors to convert raw data from OncoVista Innovative's financial statements into concise, actionable information that can be used to evaluate the performance of OncoVista Innovative over time and compare it to other companies across industries.| Return On Asset | -23.58 | |||
| Beta | -51.97 |
OncoVista Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining OncoVista Innovative's current stock value. Our valuation model uses many indicators to compare OncoVista Innovative value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across OncoVista Innovative competition to find correlations between indicators driving OncoVista Innovative's intrinsic value. More Info.OncoVista Innovative Therapies is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the OncoVista Innovative's earnings, one of the primary drivers of an investment's value.OncoVista Innovative Systematic Risk
OncoVista Innovative's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. OncoVista Innovative volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on OncoVista Innovative correlated with the market. If Beta is less than 0 OncoVista Innovative generally moves in the opposite direction as compared to the market. If OncoVista Innovative Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one OncoVista Innovative is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of OncoVista Innovative is generally in the same direction as the market. If Beta > 1 OncoVista Innovative moves generally in the same direction as, but more than the movement of the benchmark.
Additional Tools for OncoVista Pink Sheet Analysis
When running OncoVista Innovative's price analysis, check to measure OncoVista Innovative's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoVista Innovative is operating at the current time. Most of OncoVista Innovative's value examination focuses on studying past and present price action to predict the probability of OncoVista Innovative's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoVista Innovative's price. Additionally, you may evaluate how the addition of OncoVista Innovative to your portfolios can decrease your overall portfolio volatility.